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Adeno-associated virus serotype 9 (AAV9)-mediated gene transfer has been reported in
central nervous system (CNS) and peripheral tissues. The current study compared the
pattern of expression of Green Fluorescent Protein (GFP) across the mouse CNS and
selected peripheral tissues after intrathecal (i.t.) or intravenous (i.v.) delivery of equivalent
doses of single-stranded AAV9 vector. After i.t. delivery, GFP immunoreactivity (-ir) was
observed in spinal neurons, primary afferent fibers and corresponding primary sensory
neurons at all spinal levels. Robust transduction was seen in small and large dorsal
root ganglion (DRG) neurons as well as trigeminal and vagal primary afferent neurons.
Transduction efficiency in sensory ganglia was substantially lower in i.v. treated mice. In
brain, i.v. delivery yielded GFP-immunoreactivity (-ir) primarily in spinal trigeminal tract,
pituitary, and scattered isolated neurons and astrocytes. In contrast, after i.t. delivery,
GFP-ir was widespread throughout CNS, with greater intensity and more abundant
neuropil-like staining at 6 weeks compared to 3 weeks. Brain regions with prominent
GFP-ir included cranial nerve nuclei, ventral pons, cerebellar cortex, hippocampus,
pituitary, choroid plexus, and selected nuclei of midbrain, thalamus and hypothalamus.
In cortex, GFP-ir was associated with blood vessels, and was seen in both neurons and
astrocytes. In the periphery, GFP-ir in colon and ileum was present in the enteric nervous
system in both i.v. and i.t. treated mice. Liver and adrenal cortex, but not adrenal medulla,
also showed abundant GFP-ir after both routes of delivery. In summary, i.t. delivery
yielded higher transduction efficiency in sensory neurons and the CNS. The observation
of comparable gene transfer to peripheral tissues using the two routes indicates that a
component of i.t. delivered vector is redistributed from the subarachnoid space to the
systemic circulation.
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INTRODUCTION
Adeno-associated virus serotype 9 (AAV9) vector has engendered
considerable interest in its therapeutic development for treating
neurological disorders (Dayton et al., 2012), in part because it
has been heralded as capable of traversing the blood brain bar-
rier to target the central nervous system (CNS), where it has
been shown to transduce astrocytes and neurons (Foust et al.,
2009; Gray et al., 2011; Samaranch et al., 2013). Enthusiasm
for using AAV9-mediated gene therapy for global CNS trans-
duction or targeting of specific neuronal populations has lead
to investigations on the optimal route of administration to the
CNS, scalability from rodent models to larger animal species, and
appropriate promoters for broad distribution, cell-specific tar-
geting, or improved duration of expression (Gray et al., 2011;
Snyder et al., 2011; Federici et al., 2012; Samaranch et al., 2012,
2013; Dirren et al., 2014). Whereas the intravenous route of
delivery of AAV9 has been examined extensively and success-
fully utilized in models of neurological disorders (Foust et al.,
2009; Fu et al., 2011; Ruzo et al., 2012; Garg et al., 2013;
Shen et al., 2013; Yamashita et al., 2013; Elmallah et al., 2014),
AAV9 administration into the CSF has been employed less fre-
quently in rodents (Snyder et al., 2011; Haurigot et al., 2013;
Hirai et al., 2014), and the biodistribution of the vector follow-
ing intrathecal delivery has not been fully characterized. This
direct CNS route of administration offers advantages such as
reduction in the vector dose required for CNS transduction, and
potentially restricted distribution, minimizing off-target effects
(Gray et al., 2011, 2013; Snyder et al., 2011; Samaranch et al.,
2013).
We and others have shown that delivery of AAV vectors
within the lumbar intrathecal space leads to expression of green
fluorescent protein (GFP) in dorsal root ganglion (DRG) neurons
as well as brain and peripheral tissues (Storek et al., 2008; Towne
et al., 2009; Mason et al., 2010; Vulchanova et al., 2010; Schuster
et al., 2013). Although AAV9-mediated transduction of primary
sensory neurons has been previously reported in rodents and
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non-human primates (Hirai et al., 2012, 2014; Gray et al., 2013),
the pattern of AAV9-driven transgene expression in sensory
ganglia has not been thoroughly examined. In the present study,
we evaluated the ability of AAV9 to transduce primary sensory
neurons as well as its distribution to brain regions due to rostral
flow of CSF when delivered intrathecally by direct lumbar
puncture. In addition, we examined the extent of GFP expression
in selected peripheral organs and tissues to assess potential
systemic redistribution of the vector or transport of the transgene
in peripheral nerves. We hypothesized that, in comparison to
titer-matched intravenous delivery, intrathecal administration
of AAV9-GFP will result in enhanced transduction of primary
sensory neurons, spinal cord and brain and reduced transduction
in peripheral tissues and organs.
MATERIALS AND METHODS
VECTOR
AAV9-GFP was purchased from the vector core at the
University of Pennsylvania (AAV9.CB7.Cl.eGFP.WPRE.rBG; cat #
AV-9-PV1963).
ANIMALS
Experimental subjects were 20–25 g adult male C57BL/6 mice
(6–8 weeks old at the time of treatment; Harlan, Madison, WI).
All experiments were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of the University of
Minnesota.
INJECTIONS
For the comparison of intrathecal (i.t.) and intravenous (i.v.)
delivery in the presence or absence of mannitol, 16 mice were
divided into four groups: mannitol +i.v. injection, manni-
tol + i.t. injection, i.t. injection only, and i.v. injection only.
Mannitol pretreatment: Mannitol is a hyperosmotic agent that
enhances intraparenchymal diffusion following intracerebroven-
tricular (i.c.v.) injection of AAV particles (Mastakov et al., 2002;
Fu et al., 2003). Previously, we observed that mannitol pre-
treatment enhanced AAV5-mediated transduction of primary
sensory neurons (Vulchanova et al., 2010) and in the present
study sought to determine whether it also impacts AAV9 par-
ticle distribution. Subjects were injected via the tail vein with
25% mannitol solution (200µL) 20min prior to i.t. or i.v. injec-
tion of AAV9-GFP. Intravenous delivery: AAV9-GFP (∼3.3 ×
1011 vector genomes) was diluted 10-fold in sterile saline for
a final injectate volume of 100µL, injected via the tail vein.
Intrathecal delivery: AAV9-GFP (10µL containing ∼3.3 × 1011
vector genomes) was delivered by direct lumbar puncture in
awake mice as previously described (Hylden and Wilcox, 1981;
Fairbanks, 2003; Vulchanova et al., 2010). In addition, 4 mice
were injected i.t. with a reduced AAV9-GFP dose (∼6.6 × 109
vector genomes) following mannitol pretreatment. Three weeks
after injection, mice were subjected to transcardial perfusion
fixation. Prior to the 3-week endpoint one mouse from the
mannitol + i.t. injection group was euthanized due to seizures.
Finally, four mice received mannitol + i.t. injection (1.73 ×
1011 vector genomes) and were evaluated 6 weeks after vector
delivery.
IMMUNOHISTOCHEMISTRY
All animals were sacrificed by perfusion fixation as previously
described (Vulchanova et al., 1997). Briefly, animals were deeply
anaesthetized and perfused with a solution of calcium-free
tyrodes solution (in mM:NaCl 116, KCl 5.4, MgCl2·6H20 1.6,
MgSO4·7H2O 0.4, NaH2PO4 1.4, glucose 5.6, and NaHCO3 26)
followed by fixative (4% paraformaldehyde and 0.2% picric acid
in 0.1M phosphate buffer, pH 6.9). Tissues were removed and
stored in PBS containing 10% sucrose and 0.05% sodium azide
at 4◦C until further use. Sections were cut at 14µm thickness
and thaw mounted onto gel-coated slides. Tissue sections were
incubated for 1 h at room temperature in diluent (PBS con-
taining 0.3% Triton, 1% BSA, 1% normal donkey serum) and
then incubated overnight at 4◦C in primary antisera diluted in
the same solution. Primary antibodies used were: chicken anti-
GFP, 1:1000 (Abcam, cat# 13970; specificity confirmed by lack
of labeling in the absence of AAV9-GFP treatment); rabbit anti-
GFP, 1:500 (Invitrogen; Eugene, OR; specificity confirmed by
lack of labeling in the absence of AAV9-GFP treatment); rab-
bit anti-GFAP, 1:1000 (ICN, Costa Mesa, CA; pattern of labeling
equivalent to that obtained with amouse anti-GFAP antibody and
consistent with exclusive staining of astrocytes); rabbit anti-Iba1
[Wako Chemicals USA, Inc.; cat# 019-1974; specificity estab-
lished based onWestern blot (Imai et al., 1996) and colocalization
with other microglial markers (Ito et al., 1998)]; rabbit anti-
calcitonin gene related peptide (CGRP), 1:1000 (ImmunoStar,
Hudson WI, cat# 24112; specificity established by preabsorption
with CGRP and unrelated peptides—manufacturer’s informa-
tion); guinea pig anti-P2X3, 1:1000 [the generation and specificity
of this antiserum is described in (Vulchanova et al., 1997)]; rat
anti-substance P (SP), 1:100, [Abd Serotec, Oxford, UK; the speci-
ficity of this antibody is described in (Riedl et al., 2009)]; rat
anti-CD31, 1:300 (BD Pharmingen, cat# 557355; pattern of label-
ing consistent with staining of blood vessels). After rinsing with
PBS, sections were incubated for 1 h at room temperature with
appropriate combinations of Cy2-, Cy3-, and Cy5- (1:300) conju-
gated secondary antisera (Jackson ImmunoResearch, West Grove,
CA). Sections were rinsed again, and in some cases, were also
incubated with DAPI nucleic acid stain for 3–5min, 300 nM
(Invitrogen; Eugene, OR) or NeuroTrace (Invitrogen) accord-
ing to manufacturer’s instructions. Following the final rinses,
sections were cover-slipped using glycerol and PBS containing
0.1% p-phenylenediamine (Sigma). Tissues from a naïve mouse
processed in parallel with the AAV9-GFP treated tissues were
included in all immunohistochemical experiments to control for
non-specific staining of the GFP antibody.
MICROSCOPY
Anatomical analysis was based on the “The Mouse Brain In
Stereotaxic Coordinates,” Second Edition (Paxinos and Franklin,
2001) and the Mouse Brain Library C57BL/6 mouse brain atlas
(Rosen et al., 2000). Images were collected on an Olympus
Fluoview 1000 confocal microscope with associated software. For
comparisons of tissues from i.t. and i.v. treated mice, images were
collected using the same microscope setting with a few exception
where adjustments were necessary to allow detection of labeling
in i.v. treated tissues or avoid saturation in i.t. treated tissues.
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Similarly image adjustments for contrast, brightness and color
in Adobe Photoshop were performed in parallel for i.t. and i.v.
treated tissues.
QUANTIFICATION OF GFP EXPRESSION IN SENSORY GANGLIA
For each ganglion, 7–8 non-overlapping images taken across 4–5
tissue sections, which were spaced by at least 56µm, were used
for analysis. Neurons were outlined based on NeuroTrace Nissl-
like labeling, and only cells with a visible nucleus were counted.
Measurements of GFP-ir fluorescence intensity and cell area were
obtained using Image J software. The intensity measurements
of unlabeled cells were used to determine the labeling thresh-
old for unbiased identification of GFP-positive neurons. For each
ganglion the number of GFP-positive neurons was determined
as percentage of all neurons in the sampled sections. The data
are expressed as Mean ± Standard Error. Statistical analysis was
performed using GraphPad Prism 5 software. Comparisons were
made using One-Way ANOVA followed by Bonferroni post-hoc
test or by t-test.
ANALYSIS OF HISTOPATHOLOGY
Routine hematoxylin and eosin staining was performed on
cryosections mounted on gel-coated slides. For each animal in
the 3-week treatment groups, 4–6 section per ganglion were
evaluated by a trained, blinded observer and scored based on
lesion number and severity. Lesion scoring: 0, No gross lesions;
1, Increased mononuclear cells without neuron loss; 2, Distinct
nodular aggregate of mononuclear cells replacing one neuron; 3,
Discrete nodular aggregates of mononuclear cells replacing more
than one neuron; 4, Mononuclear infiltrates and nodular aggre-
gates replacing at least three neurons. For each ganglion, average
lesion score was calculated based on the lesion score of each of the
examined sections. The data is reported as mean± SE of the aver-
age lesion score for each experimental group. Tissues included
dorsal root ganglia, spinal cord, liver, skeletal muscle, ileum, and
colon.
RESULTS
AAV9-MEDIATED TRANSDUCTION OF PRIMARY SENSORY NEURONS
AND THEIR CNS PROJECTION TARGETS
Three weeks after i.t. AAV9-GFP delivery, intense GFP-ir was
observed at all levels of spinal cord (Figures 1A–D). GFP-ir fibers
were abundant in dorsal horn and dorsal columns, and label-
ing was seen in neuronal cell bodies in both dorsal and ventral
horn (Figures 1E,F). In contrast, i.v. delivery of the viral vector
resulted in limited labeling of fibers in dorsal horn and isolated
cell bodies in ventral horn (Figures 1G,H). Consistent with the
observations in spinal cord, GFP-positive neurons were present
in DRG (Figure 2). Quantitative image analysis indicated that
73± 12% of L4 DRG neurons were GFP-positive after i.t. delivery
(range 47–95%, n = 4), compared to 9 ± 1% after i.v. delivery
(range 7–10%, n = 4) (Figure 4A). Mannitol pretreatment did
not significantly enhance the transduction of DRG neurons by
AAV9-GFP after i.t. or i.v. delivery (Figure 4A). Reduction in the
number of viral particles delivered i.t. (50× dilution) correspond-
ingly lead to reduction of the number of labeled neurons to 8 ±
4% (range 2–15%, n = 4). Analysis of the size distribution of
FIGURE 1 | (A–H) Localization of GFP-ir in the spinal cord 3 weeks after i.t.
(IT) or i.v. (IV) delivery of AAV9-GFP without mannitol. (A–D), GFP-ir in
cervical (A), thoracic (B), lumbar (C), and sacral (D) spinal cord after i.t.
delivery. (E,F) GFP-ir in dorsal (DH, E) and ventral (VH, F) horn of lumbar
spinal cord after i.t. delivery. (G,H) GFP-ir in lumbar spinal cord (G) and
ventral horn (VH, H) after i.v. delivery. Scale bars: 200µm in (A–D), and (G);
100µm in (E,F,H).
GFP-positive DRG neurons suggested preferential transduction of
large-diameter neurons, particularly after i.t. delivery of the 1/50
dose and after i.v. delivery (Figure 4B). However, i.t. delivery of
full-strength AAV9-GFP resulted in substantial transduction of
small-diameter DRG neurons (64 ± 17% of all small-diameter
neurons, range 27–94%; Figure 4B), which was also illustrated by
the frequent colocalization of GFP-ir with the markers of pep-
tidergic and non-peptidergic small-diameter neurons, CGRP and
P2X3 (Figures 2A–C).
AAV9-GFP transduction was also observed in the trigemi-
nal sensory system (Figures 3A–D). Similar to spinal cord, GFP
labeling in the spinal trigeminal tract and nucleus was substan-
tially more abundant after i.t. delivery compared to i.v. delivery
(Figures 3A,C). In trigeminal ganglia, GFP-ir was present in 52 ±
7% (range 37–69%, n = 4) and 21 ± 3% (range 15–27%, n =
4) of neurons in the i.t. and i.v. treatment groups, respectively
(Figure 4A). Notably, the number of GFP-positive neurons after
i.v. delivery was significantly higher in trigeminal ganglia com-
pared to DRG (Figure 4A). As in DRG, mannitol pretreatment
did not enhance the transduction of trigeminal sensory neu-
rons. Finally, in addition to DRG and trigeminal ganglia, in i.t.
treated mice GFP-ir was also seen in the vagal sensory system
(Figures 3E–G). Labeling in the solitary tract and its associated
nucleus was seen throughout their rostral-caudal extent (caudal
medulla shown in Figure 3E). GFP-ir was also present in neurons
of the nodose ganglion in i.t. treated mice. In i.v. treated mice
detection of faint GFP-ir in the region of the solitary tract and
nucleus was only seen using higher magnification and laser power
(Figure 3G).
In the course of quantitative image analysis, we noted abnor-
mal Nissl labeling, visualized by NeuroTrace, in some sections.
This included intensely GFP-labeled neurons that were devoid
of NeuroTrace staining (Figures 5A,B, arrows) as well as mor-
phology consistent with satellite cell proliferation (Figures 5A,B,
arrowhead). Subsequent histopathological evaluation revealed
the presence of mononuclear aggregates and infiltrates in DRG,
and to a lesser extent in trigeminal ganglia, of mice receiving i.t.
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FIGURE 2 | Localization of GFP-ir in lumbar DRG 3 weeks after i.t. or i.v.
delivery of AAV9-GFP without mannitol. (A–C) GFP-ir in L4 DRG after i.t.
delivery and its relationship to CGRP- (B) and P2X3-ir (C) Arrows and
arrowheads indicate colocalization of GFP- and CGRP-ir and GFP- and P2X3-ir,
respectively. (D) GFP-ir in L4 DRG after i.v. delivery. Scale bar: 100µm.
AAV9. Lesions ranged in severity from infrequent, discrete nod-
ules of residual satellite glial cells replacing solitary neurons to
exuberant satellite glial cell proliferation withmultifocal neuronal
necrosis and loss. The mean lesion score for i.t. treated mice was
1 ± 0.8 for DRG, and 0.03 ± 0.2 for TG, and for i.t.+mannitol
treated mice was 2.5± 1.2 for DRG and 0.8± 0 for TG (for the i.v.
treatment groups the mean score was<0.05). A cursory examina-
tion of other tissues, including spinal cord, liver, skeletal muscle,
and gut, did not reveal additional lesions.
AAV9-MEDIATED GFP EXPRESSION IN THE CNS
Expression of GFP in the CNS was examined using immunohis-
tochemistry across several brain regions 3 weeks after intravenous
(i.v.) or intrathecal (i.t.) delivery of AAV9-GFP (Figures 6–10).
Overall, i.v. delivery of vector resulted in substantially lower
GFP-ir in brain compared to i.t. delivery. In i.v. treated mice,
low-intensity GFP-ir was seen in isolated neurons throughout the
brain without an apparent association with specific CNS regions
(Figures 3G, 7A2-IV, 9B). GFP labeling was also present in astro-
cytes and outlined CNS blood vessels following i.v. treatment
(Figure 9B).
FIGURE 3 | Localization of GFP-ir in spinal trigeminal nucleus and
nucleus of the solitary tract (NTS) and their corresponding sensory
ganglia. (A–D) GFP-ir in the spinal trigeminal nucleus (A,C) and trigeminal
ganglion neurons (B,D) after i.t. (A,B) or i.v. (C,D) delivery. (E–G)
Localization of GFP-ir in NTS (arrows, E) and the nodose ganglion (F) after
i.t. delivery, and in NTS after i.v. delivery (G). Detection of labeling in G
required higher magnification and laser power than in E. Scale bars: 200µm
in (A,C,E); 100µ min (B,D,F,G).
The localization of GFP-ir in brains of i.t. treated mice is
described below. All brain regions where GFP-ir was observed
in neuronal cell bodies are listed in Table 1. Unlike the scat-
tered pattern of neuronal labeling seen after i.v. delivery, in brains
from i.t. treated mice the majority of GFP-positive neurons were
seen within discrete nuclei and in some cases within subdivisions
of certain nuclei. However, there were also numerous instances,
particularly in cortex, where clusters of intensely labeled cells
were sporadically associated with blood vessels rather than with
a particular anatomical region. Astrocytes were always seen in
association with blood vessels. It is unclear at present what fac-
tors govern the vasculature-related access of viral particles to CNS
parenchyma.
Medulla, pons, and cerebellum
Within cranial nerve (Cn) nuclei, GFP-ir was abundant in gracile,
cuneate (Figures 6B,C), external cuneate, spinal (Figures 3A,B,
6B,C), and chief sensory trigeminal nuclei as well as in the nucleus
of the solitary tract (Figures 3E,G). Labeling was also present in
vestibular and cochlear nuclei and in some motor nuclei of cra-
nial nerves. GFP-ir in neurons and fibers appeared to be more
abundant in cochlear nuclei compared to vestibular and, within
the vestibular nuclear complex, more abundant in caudal than
in rostral regions. In motor nuclei, GFP-ir was most promi-
nent in neurons of the facial nucleus, followed by hypoglossal,
whereas neurons of the trigeminal motor nucleus were faintly
labeled. We could not establish conclusively whether GFP-ir was
present in the mesensephalic trigeminal nucleus, dorsal motor
nucleus of cranial nerve X (CnX), and the nuclei of CnXI, CnVI,
CnIV, and CnIII. In the medulla and pons, GFP-ir cell bodies
were also found in the area postrema, inferior olivary nuclei,
the superior olivary complex, nuclei of the lateral lemniscus, and
pontine muclei, which are shown in Figure 7B1. Labeling in the
raphe nuclear complex was not conclusively detected. GFP-ir was
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FIGURE 4 | Quantitative image analysis of the transduction of sensory
neurons. (A) Analysis of the proportions of GFP-positive DRG and
trigeminal ganglion (TG) neurons [n = 4 for i.t. (IT) and i.v. (IV) groups;
n = 2 for i.t. and i.v. groups with mannitol pretreatment (IT+M and IV+M,
respectively)]. ∗, indicates significant difference between i.t. and i.v.
treatment groups in DRG and TG (p < 0.005; One-Way ANOVA for each
type of ganglia followed by Bonferroni post-hoc test). #, indicates
significant difference between DRG and TG in the i.v. treatment group
(p < 0.01; t-test). (B) Analysis of the proportions of small-diameter
(≤22 um) and large-diameter (>22um) GFP-positive DRG neurons. ∗,
indicates significant difference between small- and large-diameter DRG
neurons in the i.v. treatment group (p < 0.005; paired t-test).
FIGURE 5 | Labeling for GFP (A) and NeuroTrace (B) shows
GFP-positive neurons devoid of NeuroTrace staining (arrows) and
clusters of satellite cell nuclei (arrowhead) indicative of gliosis. Scale
bar: 100µm.
observed in all layers of cerebellar cortex (Cb; Figure 6B). Fiber-
like labeling, presumably originating from Purkinje cells, was
present in the deep cerebellar nuclei (not shown), but we saw no
evidence of labeling of neurons within the nuclei.
Midbrain
In midbrain, GFP-ir was most prominent in clusters of neurons
in layer 2 of the inferior colliculus, and neurons in the internal
gray layer of the superior colliculus (Figure 7A1). In the sub-
stantia nigra GFP-ir neurons were noted in the ventral region of
pars reticulata at caudal levels and at more rostral levels neurons
were also present in the ventromedial portion of pars compacta.
Labeling was also observed in the interpeduncular nucleus and
parabrachial nucleus and to a lesser extent the ventral tegmental
area. All other regions of midbrain, including the periaqueductal
gray and the red nucleus, were devoid of GFP-ir neurons.
Thalamus, hypothalamus, and pituitary
With the exception of the medial geniculate nucleus (MGN),
which contained many GFP-positive neurons in all subdivisions
(Figure 7B2), relatively little GFP labeling was observed in the
caudal nuclei of the thalamus. Faintly labeled neurons were noted
in lateral geniculate and lateral posterior thalamic nuclei as well
as in the region of ventroposterior lateral and medial nuclei. In
the anterior thalamic nuclei, there were many GFP-ir fibers and a
few neuronal cell bodies (Figure 7D1). Axons of the mammillo-
thalamic tract (mt) could be observed crossing into the anterior
FIGURE 6 | Representative images of GFP-ir in medulla and cerebellum
3 weeks after i.t. (IT) or intravenous i.v. (IV) AAV9-GFP delivery. (A)
Coronal section labeled with cresyl violet was selected from the Mouse
Brain Library (Rosen et al., 2000) C57BL/6 mouse brain atlas. Inset
indicates approximate relative location of images shown in (B,C). (B) GFP-ir
associated with cuneate nucleus (Cu), spinal nucleus of V (SpV), and
cerebellar cortex (Cb) after i.t. delivery. (C) Limited GFP-ir in cuneate and
spinal trigeminal nucleus after i.v. delivery. Scale bar: 100µm.
nuclear complex of the thalamus (Figure 7D1). In the hypothala-
mus, GFP-ir neurons and nerve fibers were observed in a number
of nuclei including portions of the mammillary nuclear com-
plex, lateral hypothalamus (Figure 7C1), and arcuate, suprachi-
asmatic, paraventricular (PeV), and supraoptic (SON) nuclei
(PeV and SON shown in Figure 7D1). Substantial GFP expres-
sion was also found in the pituitary gland (Figure 8D). Labeling
in the anterior pituitary (∧ in Figures 8D,E) was comparable
between i.t. and i.v. delivery, however, labeling in the posterior
pituitary (+ in Figures 8D,E) was consistently more intense in
animals that received i.t. vector. The increase in posterior pituitary
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FIGURE 7 | Representative images of GFP-ir in midbrain and
diencephalon. Coronal sections labeled with cresyl violet were
selected from the Mouse Brain Library (Rosen et al., 2000) C57BL/6
mouse brain atlas. Insets indicate approximate relative location of
images shown in the associated panels. (A) Panel A1: GFP-ir in
superior colliculus. Neuronal cell bodies appear as a band of puncta in
the internal gray layer of the superior colliculus. Arrows indicate
clusters of astrocytes associated with blood vessels. Panel A2:
Intense GFP-ir is present in presubiculum (PrS) and alveus (alv) of the
hippocampal formation after i.t. delivery, whereas after i.v. delivery
labeling is limited to isolated cells (arrows). (B) Panel B1: GFP-ir in
pontine nuclei and transverse pontine fibers. Panel B2: GFP-ir in the
medial geniculate nucleus (MGN) of the thalamus, hippocampal
formation, and temporal cortex. GFP-ir is present in many neurons of
the polymorph (PoDG) and granular layers (GrDG) of the dentate gyrus
as well as in nerve fibers of the molecular layer of dentate gyrus
(Mol), stratum lacunosum-moleculare (LMol), and alveus (alv). Asterisks
indicate blood vessels in proximity to clusters of labeled cells in
cortex. (C) Panel C1: GFP-ir in lateral hypothalamus (LH) and
mammilothalamic tract (mt). Panel C2: GFP-ir in the rostral-dorsal
hippocampal formation. The molecular layer of the dentate gyrus (Mol),
stratum lacunosum-moleculare (LMol), and alveus (alv) are highlighted
by GFP-ir. (D) Panel D1: GFP-ir in the lateral dorsal nucleus (LD) of
thalamus and in axons from the mammillo-thalamic tract (mt) entering
portions of the anterior nuclear complex (AD and AV). Labeling is also
present in the fornix (f), paraventricular (PeV), and supraoptic (SON)
nuclei of hypothalamus, the hippocampal commissure (hc), and choroid
plexus of the third (3V) and lateral ventricles (LV). Panels D2 IV and
ITillustrate the difference in cortical expression between delivery
routes. Asterisk indicates a blood vessel surrounded by GFP-ir cells.
Scale bars: 100µm in all panels except Panel D1, for which the scale
bar is 250µm.
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FIGURE 8 | Localization of GFP-ir in olfactory bulb and pituitary gland.
(A) Coronal section labeled with cresyl violet was selected from the Mouse
Brain Library (Rosen et al., 2000) C57BL/6 mouse brain atlas. Inset
indicates approximate relative location of images shown in (B,C). (B) After
i.t. delivery, GFP-ir was found throughout the olfactory bulb, but was most
intense in the glomerular (Gl) and external plexiform (EPl) layers. (C) Limited
GFP-ir in olfactory bulb after i.v. delivery. (D,E) Localization of GFP-ir in
pituitary. Labeling in anterior pituitary (∧) was comparable between delivery
routes; however, labeling in posterior pituitary (+) appeared more intense
after i.t. (D) delivery compared to i.v. (E). Scale bars: 100µm.
expression associated with i.t. delivery corresponded well with
labeling observed in the paraventricular (PeV) and supraoptic
nuclei (SON) of the hypothalami of i.t. treated animals.
Hippocampal formation and amygdaloid complex
There was intense GFP-ir in the presubiculum (PrS;
Figure 7A2-IT), parasubiculum, and subiculum. In the cau-
dal portions of the dentate gyrus (DG), many neuronal cell
bodies were observed in the polymorph (PoDG) and granular cell
(GrDG) layers. The molecular layer (Mol) of the dentate gyrus
and the stratum lacunosum-moleculare (LMol) of the hippocam-
pus were clearly defined by GFP-ir both in the caudal-ventral
(Figure 7B2) and rostral-dorsal (Figure 7C2) portions of the hip-
pocampal formation. However, the rostral-dorsal hippocampus
contained very few GFP-positive neurons compared to more
caudal and ventral regions. GFP-ir was also noted in fibers enter-
ing the alveus of the hippocampus (alv; Figure 7B2) and well
as fibers within the fornix (f) and the hippocampal commissure
(hc) (Figure 7D1). In addition to hippocampus, GFP-ir was
observed in portions of the amygdaloid complex (not shown).
Cortex, forebrain, and olfactory bulb
In the forebrain GFP-ir was prominent in the islands of Calleja,
nuclei of the diagonal band, ventral pallidum, preoptic area,
FIGURE 9 | Representative images of GFP-ir cells in cortex. (A) After i.t.
administration, intensely labeled clusters of cells were observed in close
proximity to blood vessels, which are indicated by small arrows. The
morphology of labeled cells was consistent with astrocytes (arrowheads)
and neurons (large arrows). (B) After i.v. delivery, GFP-labeling was
associated with blood vessels (small arrows) as well as isolated neurons
(large arrow) and astrocytes (arrowhead). Scale bar: 50µm.
FIGURE 10 | GFP-ir in choroid plexus of the fourth ventricle. GFP-ir
(green) is present in many epithelial cells (examples indicated by arrows)
after i.t. delivery (A) whereas labeling after i.v. delivery is limited (B). Blood
vessels within the choroid plexus are visualized using CD31 (purple). Scale
bar: 100µm.
and septal nuclei (not shown). Labeling of neuronal cell bod-
ies was not seen in the nucleus accumbens and was limited in
the striatum. Intense GFP labeling was observed in the olfactory
tubercle (not shown) and olfactory bulbs (Figure 8B). GFP-ir
was found throughout the olfactory bulb in nerve fibers, neu-
ronal cell bodies and astrocytes, but was most concentrated in
themedial portions of the glomerular (Gl) and external plexiform
(EPl) layers. In cortex, GFP-ir neurons and astroglia were found
in clusters that were often very near to larger blood vessels (see ∗
in Figures 7B2,D2-IT; small arrows in Figure 10A). This associ-
ation was particularly striking near the surface of the cortex. The
clusters appeared to be most prominent in entorhinal, retrosple-
nial, and cingulate cortex. With i.v. delivery, isolated GFP-positive
astrocytes and neurons were also in proximity to labeled blood
vessels (Figure 10B), however, association with large blood vessels
near the cortical surface was not observed.
Choroid plexus
Labeling of choroid plexus was seen throughout the ventric-
ular system (third (3V) and lateral (LV) ventricles shown in
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Table 1 | Relative abundance of GFP-ir neurons in CNS regions that
were transduced by AAV9: +, sporadic; ++, consistent intermediate;
+++, consistent abundant; ++++, very abundant (e.g., cerebellum,
Figure 6B, and olfactory bulb Figure 8B).
CNS subdivision Structure
Medulla and pons gracile n. +++
cuneate n. +++
external cuneate n. +++
spinal n. of CnV +++
hypoglossal n. +++
nucleus of the solitary tract +++
area postrema +++
reticular formation ++
inferior olivary complex ++
vestibular nuclear complex ++
cochlear nuclear complex +++
principal sensory n. of CnV +
motor n. of CnV +
facial nucleus +++
superior olivary complex ++
pontine nuclei +++
nuclei of the lateral lemniscus +++
Cerebellum Purkinje cell layer ++++
granule cell layer ++++
Midbrain inferior colliculus (external cortex and
dorsal n.)
++
superior colliculus (internal gray layer,
medial zone of deep gray layer)
++
ventral tegmental area +
substantia nigra, reticulata (ventral
portion only)
++
substantia nigra, compacta (rostral
vntromedial portion)
++
interpeduncular nucleus (caudal and
lateral divisions)
++
parabrachial nuclear complex +
Thalamus medial geniculate n. +++
lateral geniculate n. +
lateral posterior n. +
ventrolateral n. +
ventromedial n. +
anterior thalamic nuclei +
Hypothalamus mammillary nuclear complex ++
arcuate n. +++
lateral hypothalamus +++
tuber cinereum ++
paraventricular n. +
ventromedial n. +
suprachiasmatic n. ++
supraoptic n. ++
(Continued)
Table 1 | Continued
CNS subdivision Structure
Forebrain hippocampal formation ++++
amygdaloid complex +++
striatum +
nuclei of the diagonal band +++
septal nuclei +++
medial preoptic area ++
ventral pallidum ++
islands of Calleja +++
cortex (sporadic clusters of neurons) ++
olfactory bulb ++++
Neuronal GFP labeling was absent or inconclusive in regions not included in the
table. The abundance of labeled neurons varied between animals at 3 weeks,
but for each animal the relative abundance in different regions was consistent.
Figures 6–8 illustrate examples from animals with higher level of labeling.
Figure 7D1). GFP-ir wasmost frequently seen in cells whosemor-
phology and localization relative to blood vessels was consistent
with that of epithelial cells (Figure 11). These cells were more
abundant in i.t. treated compared to i.v. treated mice. Other GFP-
positive cell types were also noted, but their identification was not
pursued in this study.
Time-dependent increase in GFP-ir
GFP-ir was more abundant at 6 weeks after i.t. vector adminis-
tration compared to 3 weeks. The intensity of labeling and the
density of labeled neurons within the regions described above
appeared to be increased. We did not note presence of GFP-ir
neurons in areas that were not labeled at 3 weeks. However, label-
ing within nerve fibers was increased throughout the brain. For
example, prominent increase in neuropil-like labeling at 6 weeks
relative to 3 weeks was seen in the striatum (CPu; Figure 11).
AAV9-MEDIATED GFP EXPRESSION IN PERIPHERAL ORGANS AND
TISSUES
GFP-ir was examined in liver, ileum, colon, adrenal gland, skele-
tal muscle, and skin 3 weeks after i.t. or i.v. AAV9-GFP delivery.
Abundant labeling was seen in the liver of both i.t. and i.v. treated
mice (Figure 12). In the ileum, GFP-ir was present predominantly
within the enteric nervous system. Labeling of nerve fibers was
prominent in themucosa, submucosa, and enteric ganglia. GFP-ir
was also seen within the cell bodies of some enteric neurons. The
abundance and pattern of GFP labeling was comparable in ileum
of i.t. and i.v. treated mice (Figures 13A,B). GFP-ir was also noted
in adipocytes associated with ileal mesentery of both treatment
groups (Figure 13C). In the colon, the density of GFP-positive
nerve fibers was substantially higher in i.t. treated compared to
i.v. treated mice (Figures 13D,E). GFP-positive myenteric neu-
rons were observed in both groups (Figure 13F), but were fewer
than in ileum. There was no apparent GFP labeling of immuno-
cytes in lamina propria of either ileum or colon. In the adrenal
gland both routes of delivery of AAV9-GFP yielded intense GFP-
ir restricted to the zona fasciculata (Figure 13G). Muscle fibers
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FIGURE 11 | GFP-ir in striatum at 3 weeks compared to 6 weeks after
i.t. delivery. (A,B) GFP-ir in striatum (CPu), 3 weeks after intrathecal
delivery of AAV9-GFP. (C,D) GFP expression in striatum 3 weeks after
intrathecal delivery of AAV9-GFP. Green insets in (A,C) are shown at higher
magnification in (B,D) respectively.
FIGURE 12 | Representative images of GFP-ir in liver 3 weeks after
AAV9-GFP administration. (A) i.t. treatment; (B) low-dose i.t. treatment;
(C) i.v. treatment; (D) naïve. Scale bar: 100µm.
within skeletal muscle were devoid of GFP-ir in both i.t. and
i.v. treated mice; however, labeling was observed within nerve
fibers with morphology consistent with axon endings of motor
neurons (Figure 13H, arrow) as well as endings within muscle
spindles (not shown). GFP-ir also appeared to be associated with
some blood vessels within the muscle (Figure 13H, arrowhead).
In dermis and epidermis of skin, GFP-ir was observed in nerve
fibers (Figure 13I), which were more abundant in i.t treated com-
pared to i.v. treated mice, consistent with the transduction levels
of sensory neurons in the two groups. Both routes of delivery
also resulted in GFP labeling of unidentified cells in the dermis
(Figure 13I).
DISCUSSION
In the present study, we examined the biodistribution in mouse
of intrathecally-delivered AAV9-GFP and compared it to the
distribution achieved by an equivalent dose of viral vector admin-
istered intravenously. Intrathecal delivery yielded higher trans-
duction efficiency in sensory neurons and the CNS. Mannitol
FIGURE 13 | Localization of GFP-ir in peripheral tissues after i.t. or i.v.
delivery of AAV9-GFP without mannitol pretreatment. (A,B) GFP-ir in
ileum after i.t. (A) or i.v. (B) delivery. Arrows indicate enteric ganglia. Scale
bar: 50µm. (C) GFP-ir (green) in adipocytes associated with ileac
mesentery. DAPI (blue) labeling of nuclei outlines blood vessels (∗). CGRP-ir
nerve fibers in the mesentery are shown in red. Scale bar: 100µm. (D,E)
GFP-ir in colon after i.t. (D) or i.v. (E) delivery. Scale bar: 50µm. (F) GFP-ir
(green, arrow) neuron within a myenteric ganglion in colon. GFP-, SP- (red),
and CGRP-ir (blue) nerve fibers are seen within the ganglion. Scale bar:
10µm. (G) GFP-ir in adrenal cortex. Dotted line indicates the edge of the
tissue. Scale bar: 200µm. (H) GFP-ir in nerve endings (arrow) and blood
vessel (arrowhead) in thigh skeletal muscle. CD31 labeling of endothelial
cells is shown in purple. Scale bar: 25µm. (I) GFP- and CGRP-ir (purple) in
skin. Arrows indicate a nerve bundle in dermis and an epidermal nerve fiber.
Scale bar: 25µm. (C,F–I) Show labeling in tissues from i.t. treated mice.
The pattern of labeling in the same tissues of i.v. treated mice was similar.
pretreatment did not appear to enhance transduction of sensory
neurons via either route of administration, as previously reported
for CNS after i.v. delivery (Gray et al., 2011). Remarkably, the
majority of peripheral tissues examined in this study were sim-
ilarly transduced following i.v. and i.t. vector delivery, suggesting
that a substantial amount of intrathecally injected viral particles
are redistributed from the subarachnoid space to the systemic
circulation.
AAV9-MEDIATED TRANSDUCTION OF PRIMARY SENSORY NEURONS
AAV9-mediated transduction of primary sensory neurons has
been previously reported in rodents and non-human primates
(Hirai et al., 2012, 2014; Gray et al., 2013). However, the pat-
tern of AAV9-driven transgene expression in sensory ganglia has
not been thoroughly evaluated. Following i.v. delivery of AAV9-
GFP, we observed GFP labeling only in approximately 10% of
DRG neurons with or without mannitol pretreatment. In con-
trast, AAV9-GFP administered i.t. at the same dose demonstrated
remarkable transduction efficiency in lumbar DRG. Over 90%
of neurons in the L4 DRG were GFP-positive in four of the
mice treated i.t. (two with and two without mannitol). The
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transduction level in DRG was dose-dependent as only 10% of
neurons were GFP-positive following a 50-fold reduction in the
dose. Based on the range of AAV9-GFP doses used in these exper-
iments and the doses used in our previous study on AAV5 and
AAV8 [approximately 3-fold lower relative to the high dose in this
study; (Vulchanova et al., 2010)], we conclude that the transduc-
tion efficiency of AAV9 in sensory neurons is superior to that of
AAV5 and AAV8 without a requirement for mannitol pretreat-
ment. Moreover, although at the low dose and after i.v. delivery
AAV9-GFP transduced predominantly large-diameter neurons, at
the high treatment dose large-diameter as well as small-diameter
peptidergic and non-peptidergic neurons were targeted. These
results suggest that AAV9 viral vectors are suitable for global
transduction of sensory neurons, unlike AAV5 and AAV8, which
target predominantly large-diameter neurons (Vulchanova et al.,
2010; Jacques et al., 2012), and AAV6, which has a preference for
small-diameter cells (Towne et al., 2009). Another notable dis-
tinction between AAV9 and AAV5 and 8 is that AAV9 yielded
more efficient transduction in thoracic spinal cord and ganglia.
AAV-mediated transduction of trigeminal ganglion sensory
neurons has not been previously described to our knowledge.
We found GFP labeling within trigeminal ganglion neurons and
nerve fibers in the spinal trigeminal nucleus after both i.t. and
i.v. vector delivery. As would be expected based on their ros-
tral location relative to the site of i.t. delivery, the number of
GFP-positive neurons was lower in trigeminal ganglia compared
to lumbar DRG. Interestingly, although as in DRG significantly
more trigeminal sensory neurons were transduced in i.t. treated
compared to i.v. treated mice, the i.v. route of administration
yielded significantly more transduced neurons in trigeminal gan-
glia compared to DRG. Further exploration of AAV9 targeting
to trigeminal ganglia by systemic vector delivery in combina-
tion with the use of sensory neuron-specific promoters may
identify strategies for selective gene transfer to trigeminal sen-
sory neurons. Finally, we also noted robust transduction of
sensory neurons in the nodose ganglia after i.t. vector delivery.
Administration of lower doses of AAV9 vectors in the cisterna
magna rather that the lumbar intrathecal space may achieve
preferential gene transfer to nodose compared to spinal gan-
glia, providing an alternative approach for the study of the vagal
sensory innervation of peripheral organs (Kollarik et al., 2010;
Gautron et al., 2011). The low level of GFP-ir in the solitary tract
after i.v. delivery indicates that transduction in nodose ganglia via
this route was limited.
AAV9-MEDIATED TRANSDUCTION IN THE CNS
The distribution of GFP labeling after intrathecal AAV9-GFP
delivery observed in the present study is consistent with that
reported by Haurigot et al. (2013) after administration of the vec-
tor in the cisterna magna, who also found expression in cerebellar
Purkinje cells, cortical neurons, hypothalamus and olfactory bulb
(Haurigot et al., 2013). The rostral distribution of viral particles
in our experiments was clearly dose-related, as we observed very
limited GFP labeling in the brain following a 50-fold dilution
of the vector. Similarly, Snyder et al. (2011) reported absence of
GFP expression in the brain after intrathecal administration of
a similar dose of AAV9-GFP (Snyder et al., 2011). The fact that
in the present study intrathecal delivery was achieved by direct
lumbar puncture in conscious subjects represents an important
distinction from delivery of the vector in CSF under conditions
of surgical anesthesia in rodents (Snyder et al., 2011; Haurigot
et al., 2013). CSF turnover in a mouse takes place within 2 h
(Rudick et al., 1982; Johanson et al., 2008), and CSF flow, and
likely viral particle distribution, is impacted by heart rate, sub-
ject position, and level of motor activity. Therefore, the pattern of
transgene expression may be affected by the specific conditions of
intrathecal delivery.
It is notable that although GFP-ir neuropil was abundant in
brains of i.t. treated mice, labeled neurons were largely restricted
to selected nuclei and cortical regions. Moreover, 6 weeks after
vector administration, there was a substantial increase in the
density of GFP-ir nerve fibers throughout the brain compared
to 3 weeks and most strikingly in midbrain, striatum, cerebel-
lum, and hippocampus. This increase was most likely due to
accumulation of anterogradely transported GFP in fine neu-
ronal processes. Although there also appeared to be more GFP-ir
neurons at the 6-week time point, neuronal cell body labeling
remained localized within the same anatomical structures seen
at 3 weeks. These observations suggest that neuronal transduc-
tion by AAV9 is not uniform throughout the CNS but restricted
to discrete regions; however, the projection pattern of the trans-
duced neurons appears to be widespread, resulting in global
axonal localization of the transgene product. Thus, intrathecally
delivered AAV9 viral vectors may be utilized for gene therapy that
targets specific CNS regions by employing appropriate promoters
as well as for global CNS distribution of transgenes whose func-
tion involves axonal release (e.g., enzymes, growth factors). The
latter scenario is relevant for conditions such as lysosomal storage
diseases, where neuropathology may be reduced through global
enzyme release (Wolf et al., 2011; Haurigot et al., 2013).
The preferential transduction of specific CNS regions is likely
influenced by viral tropism. Glycans containing terminal galac-
tose have been identified as cell-surface binding moieties for
AAV9 (Bell et al., 2011; Shen et al., 2011), but their availability
in specific CNS regions has not been characterized. Interestingly,
manipulation of cell-surface glycans altered viral AAV9 tropism
(Bell et al., 2011; Shen et al., 2012), suggesting that the pattern
of AAV9-mediated gene transfer is likely affected by changes in
glycosylation patterns under normal and disease conditions. This
possibility should be addressed in the pre-clinical development of
gene therapies. In addition, our observations indicate that the vas-
culature may contribute substantially to CNS transduction after
i.t. delivery of AAV9. Association of GFP-ir cells with blood ves-
sels was observed throughout the CNS, but was most striking
near the cortical surface of i.t. treated but not i.v. treated mice.
A relationship between AAV9-mediated transgene expression and
blood vessels was also noted by Samaranch et al. (2012). We
speculate that access of viral particles in the CSF to the perivas-
cular space contributes to AAV9-mediated transduction in CNS
parenchyma. The pattern of AAV9-driven GFP expression in the
CNS may also be influenced by anterograde and/or retrograde
transport of viral particles. Samaranch et al. (2014) reported that
injection of AAV9-GFP in the striatum resulted in GFP labeling of
neurons in substantial nigra and cortex (Samaranch et al., 2014).
Frontiers in Neuroanatomy www.frontiersin.org June 2014 | Volume 8 | Article 42 | 10
Schuster et al. AAV9-GFP biodistribution
In our study we noted GFP expression in neurons of specific
CNS pathways. For example, GFP labeling was observed at all
levels of the auditory pathway as well as in regions projecting to
hippocampus (e.g., entorhinal cortex) and receiving projections
from it (e.g., subiculum, mammillary nuclear complex). These
observations are consistent with a contribution of axonal trans-
port of viral particles to AAV9-mediated transgene expression.
The complexity of factors influencing AAV9-mediated transgene
distribution in the CNS is highlighted by the fact that regions in
which GFP-positive neuronal cells bodies were limited or absent
in our study, such as striatum and a large portion of the thala-
mus, were robustly transduced following intraparenchymal vector
administration. It is possible that neurons in these areas express
cell-surface receptors for AAV9 and transduction is enabled after
intraparenchymal injection because of overcoming of accessibil-
ity barriers. Alternatively, the high local concentrations of vector
achieved after intraparenchymal injection may enable entry of
AAV9 via binding to low-affinity cell-surface binding sites.
The limited CNS distribution of GFP-ir after i.v. deliv-
ery observed in our experiments is consistent with previously
reported transduction mediated by single-stranded AAV9 vec-
tor (Gray et al., 2011). However, the widespread correction of
CNS abnormalities in several mouse disease models (Fu et al.,
2011; Ruzo et al., 2012; Garg et al., 2013; Yamashita et al., 2013)
contradicts our observations. This apparent discrepancy may be
explained by several experimental variables including the type of
vector (i.e., single-stranded vs. self-complementary), dose, and
duration of transgene expression. It has been demonstrated that
self-complementary AAV vectors result in more robust transgene
expression compared to single-stranded (Gray et al., 2011) albeit
at the expense of packaging capacity. Our comparison of different
doses and duration of transgene expression supports the contri-
bution of these variables in achieving widespread CNS expression.
Finally, we cannot rule out the possibility that GFP expression is
more widespread than the levels detectable by fluorescence. It is
possible that functionally relevant transgenes are effective at lower
expression levels than those required for detection of reporter
gene expression.
EVALUATION OF POTENTIAL AAV9-GFP INDUCED NEUROTOXICITY
Recently, AAV9-mediated CNS expression of “non-self” proteins,
and GFP in particular, has been reported to induce neuroin-
flammation and neurotoxicity (Ciesielska et al., 2013; Samaranch
et al., 2014). Based on labeling with Iba1, we did not observe reac-
tive microglia in association with GFP-expressing CNS regions
following i.v. or i.t. vector delivery, suggesting that CNS neu-
roinflammation was absent under our experimental conditions.
This observation is consistent with the proposal that the extent
of AAV9-mediated immune activation in the CNS may be depen-
dent on a number of factors, including levels of transgene expres-
sion (Samaranch et al., 2014). Although we did not observe signs
of CNS inflammation or neurotoxicity, in DRG, and to a lower
extent trigeminal ganglia, of mice given intrathecally the high
treatment dose we noted mononuclear aggregates and infiltrates
that appeared to be associated with neuronal damage. As GFP
labeling in neurons was very robust in those DRG, it is possi-
ble that GFP overexpression resulted in immune activation in the
ganglia or in disruption of protein synthesis necessary for normal
cell functioning in individual neurons. A relationship between
high levels of GFP expression and neurotoxicity is consistent with
the observation of intensely GFP-positive cells in which Nissl
staining (i.e., ribosomes) was absent. Stereological analysis appro-
priate for evaluation of cell loss was beyond the scope of this study.
However, we noted that sample sizes and proportions of large-
and small-diameter neurons were similar in ganglia from i.t. and
i.v. treated mice, suggesting that the observed histopathology did
not affect our quantitative analysis of proportions of GFP-positive
sensory neurons and that the extent of neuronal damage may
be limited. Finally, the histopathology was more limited in DRG
from mice in the 6-week treatment group, which received viral
vector from a different lot, raising the possibility that viral vec-
tor preparation may also be a factor. In the context of other
reports of GFP-related toxicity (Ciesielska et al., 2013; Samaranch
et al., 2014) and themultifactorial determinants of AAV-mediated
gene transfer, the present observations call for increased vigilance
in evaluating outcomes of AAV9-driven transgene expression in
sensory neurons.
DISTRIBUTION OF AAV9-MEDIATED GFP EXPRESSION IN PERIPHERAL
TISSUES AND ORGANS
The present study extends previous observations on the periph-
eral distribution of AAV9-mediated gene transfer (Zincarelli
et al., 2008; Fu et al., 2011; Benkhelifa-Ziyyat et al., 2013) and
is consistent with the correction of peripheral pathology after
AAV9-mediated gene transfer in a mouse model of a lysoso-
mal storage disease (Haurigot et al., 2013). Transduction in the
liver was robust and equivalent for i.v. and i.t. delivery. In mice
treated i.t. with a 50-fold lower vector dose, GFP-expression in
liver was reduced but still appeared uniform. In contrast to these
observations, Samaranch et al. (2012) reported very low GFP
expression in liver of non-human primates, in which AAV9-GFP
was administered in the cisterna magna (Samaranch et al., 2012).
It is unclear whether this difference in peripheral transduction is
due to dosing differences, type of AAV9 vector (single-stranded
vs. self-complementary), or species differences in the extent to
which AAV9 vectors are redistributed to the systemic circulation
following delivery in the CSF. The potential for such substantial
species differences in viral vector distribution between rodent and
primate pre-clinical models should be given serious consideration
in the translational development of gene therapies.
Our findings of extensive labeling in the enteric nervous sys-
tem are in agreement with a previous description of transduction
in enteric ganglia (Fu et al., 2011). Interestingly, while the pat-
tern of GFP-ir was similar in the ileum of i.t. and i.v. treated mice,
in the colon GFP-ir was substantially more abundant following
i.t. vector delivery. Furthermore, transduction of intrinsic enteric
neurons was less frequent in colon compared to ileum following
both routes of delivery. These observations suggest that the ileum
is more accessible than colon to systemically available AAV9 viral
particles for reasons that are presently unclear. Additionally, the
extensive GFP labeling in the colon of i.t. treated mice is likely
to be associated with nerve fibers of extrinsic sensory neurons
whose cell bodies are located within DRG as we have previously
described for AAV8-mediated GFP expression in colon (Schuster
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et al., 2013). It is also likely that a proportion of the GFP-ir
nerve fibers in colon as well as ileum are vagal primary affer-
ents since in the present study we noted transduction of sensory
neurons in nodose ganglia. In addition to GFP labeling within
the enteric nervous system, non-neuronal GFP-positive cells were
occasionally encountered in both ileum and colon. The identity of
these cells remains to be determined. While evaluating GFP label-
ing in the ileum, we noted transduction of adipocytes with the
associated mesentery. Although GFP labeling of more prominent
depots of white adipose tissue was not examined in the present
study, this observation raises the possibility that AAV9 vectors
may be useful for gene transfer to adipocytes.
Our analysis of AAV9-mediated transduction in the periph-
ery included the adrenal gland, which to our knowledge has not
been previously evaluated. A similar pattern of GFP expression
was observed after i.t. and i.v. delivery of the vector. Interestingly,
GFP-ir appeared to be restricted to the zona fasciculata of the
adrenal cortex withminimal labeling in the other layers of the cor-
tex or in the adrenal medulla. A similar pattern of labeling with
reduced intensity was observed at the lower treatment dose used
in this study. These observations suggest potential utility of AAV9
for genetic manipulation of glucocorticoid-producing endocrine
cells.
Under the present experimental conditions, transduction of
skeletal muscle was not observed, in contrast with previous
reports (Zincarelli et al., 2008; Foust et al., 2009; Fu et al.,
2011; Elmallah et al., 2014). This discrepancy could be due to
differences in type of AAV9 vector (i.e., single-stranded vs. self-
complementary), dose, or time point of tissue evaluation. The
observation of GFP-positive nerve endings in skeletal muscle
is consistent with GFP expression in spinal motor and sensory
neurons. Similarly, the presence of GFP-positive nerve fibers in
dermis and epidermis is in agreement with the observed trans-
duction of sensory neurons. The identity of other GFP-positive
structures in the dermis is presently unknown. We speculate that
they may correspond to blood vessels as instances of GFP labeling
of blood vessels were also observed in skeletal muscle and intes-
tine. These findings may reflect AAV9-mediated transduction of
endothelial cells and require further investigation.
CONCLUSIONS
The present analysis of the biodistribution of single-stranded
AAV9-GFP following intrathecal or intravenous delivery yielded
several important observations related to AAV9-mediated gene
transfer in the central and peripheral nervous system. Intrathecal
administration of AAV9-GFP resulted in global transduction of
lumbar DRG neurons as well as efficient transduction of trigemi-
nal and nodose ganglion neurons. The adverse effects of transgene
expression noted in DRG neurons suggest that the possibility for
tissue-dependent, titer-and time-related toxicity associated with
gene transfer should be considered and assessed on a case-by-case
basis for each serotype and gene employed. Intrathecally deliv-
ered AAV9-GFP yielded broad CNS expression of GFP that was
substantially elevated relative to intravenous delivery. The pattern
of CNS transduction is not uniform and is likely to be influenced
by factors such as axonal transport and interactions of viral par-
ticles with elements of the blood-brain barrier. Finally, in several
peripheral tissues transduction was comparable following i.t. or
i.v. delivery, suggesting substantial systemic redistribution of i.t.
injected AAV9-GFP. In summary, the present study demonstrates
that the intrathecal route of administration results in AAV9-
mediated gene transfer to a broad spectrum of discrete central and
peripheral nervous system regions as well as peripheral organs in
a dose-dependent and time-dependent manner.
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